On the Etiology of Type 1 Diabetes A New Animal Model Signifying a Decisive Role for Bacteria Eliciting an Adverse Innate Immunity Response by Korsgren, Stella et al.
The American Journal of Pathology, Vol. 181, No. 5, November 2012
Copyright © 2012 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajpath.2012.07.022Immunopathology and Infectious Diseases
On the Etiology of Type 1 Diabetes
A New Animal Model Signifying a Decisive Role for Bacteria
Eliciting an Adverse Innate Immunity ResponseStella Korsgren,* Ylva Molin,† Kaija Salmela,‡
Torbjörn Lundgren,§ Åsa Melhus,† and
Olle Korsgren*
From the Department of Immunology, Genetics, and Pathology,*
Rudbeck Laboratory, and the Department of Medical Sciences,†
Section of Clinical Microbiology, Uppsala University, Uppsala,
Sweden; the Division of Transplantation,‡ Surgical Hospital,
Helsinki University, Helsinki, Finland; and the Division of
Transplantation Surgery,§ CLINTEC, Karolinska Institute,
Stockholm, Sweden
The cause of type 1 diabetes (T1D) remains unknown;
however, a decisive role for environmental factors is
recognized. The increased incidence of T1D during the
last decades, as well as regional differences, is paralleled
by differences in the intestinal bacterial flora. A new
animalmodel was established to test the hypothesis that
bacteria entering the pancreatic ductal system could
trigger -cell destruction and to provide new insights to
the immunopathology of the disease. Obtained findings
were compared with those present in two patients dy-
ing at onset of T1D. Different bacterial species, present
in the human duodenum, instilled into the ductal
system of the pancreas in healthy rats rapidly in-
duced cellular infiltration, consisting of mainly neutro-
phil polymorphonuclear cells and monocytes/macro-
phages, centered around the pancreatic ducts. Also, the
islets of Langerhans attracted polymorphonuclear cells,
possibly via release of IL-6, IL-8, and monocyte chemot-
actic protein 1. Small bleedings or large dilatations of
the capillaries were frequently found within the islets,
and several -cells had severe hydropic degeneration
(ie, swollen cytoplasm) but with preserved nuclei. A
novel rat model for the initial events in T1D is pre-
sented, revealing marked similarities with the morpho-
logic findings obtained in patients dying at onset of T1D
and signifying a decisive role for bacteria in eliciting an
adverse innate immunity response. The present find-
ings support the hypothesis that T1D is an organ-spe-cific inflammatory disease. (Am J Pathol 2012, 181:
1735–1748; http://dx.doi.org/10.1016/j.ajpath.2012.07.022)
Our understanding of the etiology of type 1 diabetes
(T1D) remains limited and originates to a large extent
from two animal models: the nonobese diabetic mouse
and the BioBreeding-diabetes prone rat.1 In both models
a progressive T-cell–mediated destruction of the -cells
occurs; however, the immunopathologic findings reveal
limited similarities with the human disease.2–5 In human
pancreatic specimens, insulitis is discrete, affects only a
few islets, and is heterogeneously distributed within the
gland. In a recent meta-analysis, insulitis was reported in
only 29% of patients with onset between 15 and 39 years
of age andwith a disease duration of1month.6 At the time
of diagnosis, autoantibodies were only present in approxi-
mately 70% to 80% of affected patients.7 Likewise, attempts
to prevent disease progression with immunosuppres-
sion8–11 or immunointerventions12–14 cause no or only tran-
sient preservation of -cell function.
The fact that the exocrine pancreas gets affected in
patients with T1D is underappreciated, and several stud-
ies have found autoantibodies in the exocrine cells before
the onset of T1D.15–18 Mild to moderate exocrine pancre-
atic insufficiency is an early event in T1D,19 and a sub-
stantial reduction (32%) in pancreatic volume is already
present 3 to 4 months after onset.20 Also, in the classic
report by Gepts,4 lesions of the acinar tissue were re-
ported to occur frequently in patients with recent onset of
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sions of acute pancreatitis with accumulation of leuko-
cytes, often centered around the excretory canals.2–5 In a
more recent study of patients with long-term T1D, 40%
had periductal fibrosis and 60% of cases had periductal
fibrosis that extended to the interlobular pancreas.21 Col-
lectively, these observations suggest that the injurious
process that causes T1D affects both the exocrine and
endocrine components of the pancreas and challenge
the view that T1D is a -cell–specific autoimmune dis-
ease.
The low concordance rate for the development of T1D
in identical twins and the current rapid increase in inci-
dence of T1D argue against a decisive role for genetic
factors. Notably, there is a close to sixfold gradient in the
incidence of T1D between Russian and Finland Karelia,
although the population is homogenous and the predis-
posing HLA genotypes are equally frequent.22 In addi-
tion, children born in Finland by immigrants from Somalia,
a low incidence country for T1D, acquire the same risk for
T1D as the native Finish population.23 On the basis of
these and similar observations, it is generally assumed
that environmental factors may act as triggers of T1D. For
decades different enteroviruses have been implicated in
the pathogenesis of T1D24; however, evidence of causal-
ity remains missing.
Bacterial colonization of the infantile gut is influenced by
environmental factors and has changed markedly in devel-
oped countries during the last decades.25 Interestingly, the
increased incidence of T1D26 and the difference in inci-
dence of T1D in Sweden, Italy, and Africa26–28 are paral-
leled by reported frequencies of intestinal Staphylococcus
aureus.29–32 Bacteria entering the ductal system of the pan-
creas would be exposed to the pancreatic juice–containing
substances, with marked antibacterial effects initiating re-
lease of bacterial components, such as lipopolysaccharide
(LPS), lipoteichoic acid (LTA), and various toxins. Notably,
these substances have been implicated in the etiology of
neurogenerative diseases and neural cell death because
they stimulate microglia to produce proinflammatory cyto-
kines (IL-1b, IL-6, tumor necrosis factor-), nitric oxide, and
reactive oxygen species, causing significant cell death in
neighboring neural cells.33
The present study was conducted to establish an an-
imal model for the initial events in T1D to test the hypoth-
esis that bacteria entering into the ductal system of the
pancreas could elicit an adverse innate immunity re-
sponse. Different bacterial species present transiently or
continuously in the human duodenum were instilled into
the ductal system of the pancreas in healthy rats. To
examine the clinical relevance of the experimental model,
obtained findings were compared with those present in
the pancreases of two patients dying at onset of T1D.
Materials and Methods
Ethics
All work involving human tissue was conducted accord-
ing to the principles expressed in the Declaration of Hel-sinki and in the European Council’s Convention on Hu-
man Rights and Biomedicine. Consent for organ donation
(for clinical transplantation and for use in research) was
obtained from the relatives of the deceased donors by
the donor’s physicians and documented in the medical
records of the deceased patient. The study was ap-
proved by the Regional Ethics Committee in Uppsala,
Sweden, according to the Act Concerning the Ethical
Review of Research Involving Humans (2003:460; permit
number Dnr 2009/043, 2009/371).
The animal experiments were in accordance with the
Swedish Animal Welfare Act (SFS 1988:534) and The
Swedish Animal Welfare Ordinance (SFS 1988:539) both
in agreement with directives 86/609/EEG and 2010/63/EU
of the European Parliament and of the Council on the Pro-
tection of Animals Used for Scientific Purposes. The ethical
application was approved by the Uppsala Laboratory Ani-
mal Ethical Committee (permit number C153/10).
Human Pancreatic Specimens
A total of 23 human pancreases were included in the
study. Two pancreases were obtained at the onset of T1D
(patients 1 and 2), and the remaining 21 were collected
consecutively from multiorgan donors of similar age and
without any known pancreatic disease in the time span
between the two T1D patients. The latter donors were
aged 29 to 40 years (mean  SD age, 35.6  0.7 years).
Patient 1
A 29-year-old, previously healthy male (HLA-A24, HLA-
B39, HLA-DR4) walked to the emergency department of
the local hospital after 2 days with increased thirst and
nausea. At arrival, patient was fully conscious, oriented
(Glasgow Coma Scale score of 15), and vomiting. Labo-
ratory test results were as follows: B-glucose, 46 mmol/L;
B-pH 6.92; P-HCO3
, 3; B-hemoglobin, 187 g/L; and
P-sodium, 125 mmol/L. Rehydration was initiated to-
gether with an i.v. bolus of short-acting insulin, 10 IU,
which was repeated after 3 hours, at which time the
B-glucose level was 31 mmol/L. Physical status deterio-
rated during transfer to another hospital. At admittance 5
hours after the initial contact, he was unconscious and
suddenly stopped breathing. The patient was intubated
and given norepinephrine. Laboratory tests revealed fur-
ther derangements: P-Na, 168 mmol/L; P-potassium, 4
mmol/L; B-hemoglobin, 115 g/L: C-reactive protein, 69
mg/L; and P-amylase, 82 kat/L. Computed tomography
(CT) revealed massive brain edema and a suspected
massive subarachnoid hemorrhage. The patient was re-
ferred to the Department of Neurosurgery, Helsinki Uni-
versity Hospital. The brain edema increased, and the
patient developed total brain infarction. The death of the
patient was considered the result of a series of compli-
cations associated with the recent onset of T1D.
Patient 2
The patient was a 40-year-old, previously healthy male
(HLA-A23/24, HLA-B27/44, HLA-DR4/7) with a history of
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3 weeks. The patient had, in addition, been treated with
clindamycin for a sore throat and a skin infection but
disrupted the treatment 2 days before admittance be-
cause of vomiting. The patient arrived at the hospital by
ambulance after being found unconscious at work. The
initial Glasgow Coma Scale rating was 12. The patient
was paretic in the right arm and leg but could answer
questions with yes or no. Laboratory tests revealed the
following: B-glucose, 33 mmol/L; a B-pH 7.29; and base
excess, 12.7 mmol/L. High levels of glucose and ke-
tones were found in the urine. The patient required 73 IU
of i.v. insulin during the following 16 hours to reach a
B-glucose level 10 mmol/L. A CT scan of the brain
showed no bleedings and the patient received thrombol-
ysis for a suspected brain infarction without clinical im-
provement. Two days after admittance, the patient’s state
deteriorated and he became unconscious. New CT re-
vealed a major infarction of an area corresponding to an
occlusion of the left medial cerebral artery. The patient
subsequently developed edema and total brain infarc-
tion. The death of this patient was also considered to be
the result of a series of complications associated with his
recent T1D debut.
Animals and Operating Procedure
Healthy, male Wistar rats weighing 250 to 300 g (Taconic,
Ry, Denmark) were used. To exclude strain-dependent
reactions, Lewis and Sprague Dawley rats were also in-
cluded in some experiments. Before the bacterial chal-
lenge, the animals were kept under standard laboratory
conditions and given water and food ad libitum.
The animals were anesthetized by intraperitoneal injec-
tion with thiobutabarbital (Research Biochemicals Interna-
Table 1. Bacteria and Culture Conditions
Bacterial
species Strain Origin Cultu
E. faecalis B1008314 Blood BHI broth
E. coli S0705198 Peritoneal
fluid
BHI broth
E. faecalis B1008314 Blood BHI broth w
CMRL-106
FBS
E. coli S0705198 Peritoneal
fluid
BHI broth w
CMRL-106
FBS
S. aureus
(preparation
A)
B0451020 Blood BHI broth
S. aureus
(preparation
B)
B0451020 Blood BHI broth
-Streptococcus B1008638 Blood Trypticase
with 10%
horse se
Fildes en
FBS, fetal bovine serum.tional, Natick, MA). At challenge, the common bile duct wasexposed through a ventral midline incision after a blunt
dissection. Via the common bile duct, 0.2 mL of a suspen-
sion was injected into the pancreas. Animals were kept
anesthetized for a period of 1 to 5 hours, after which they
were sacrificed by heart puncture. Control animals were
either sacrificed without any prior treatment or inoculated
with brain heart infusion (BHI) broth without bacteria.
Plasma and serum samples were assayed for aspartate
transaminase, alanine aminotransferase, alkaline phospha-
tase, antitrypsin, orosomucoid (1-acid glycoprotein), hap-
toglobin, and C-reactive protein at the Department for Clin-
ical Chemistry, Uppsala University Hospital. Biopsies were
fixed in 4% paraformaldehyde and prepared for paraffin
embedding.
Bacterial Strains and Preparation of Inocula
Four different bacterial species were used (Table 1). All
strains were clinical isolates from the Department of Clin-
ical Microbiology, Uppsala University Hospital, Uppsala,
Sweden. The bacterial choice was based on a docu-
mented ability of these bacteria to translocate into the
pancreas, liver, and/or gallbladder and to be leading
causes of infections in these organs.34–37 The S. aureus
strain produced toxic shock syndrome toxin 1, the most
common toxin harbored by S. aureus isolated from chil-
dren,38 to make it possible to study the effects of a potent
exotoxin, in addition to the endotoxin of Escherichia coli.
The bacteria were stored at 70°C, and all cultures
were initially inoculated from these frozen stocks onto
blood or chocolate agar (Acumedia Manufacturers, Lan-
sing, MI). The bacteria for pancreatic challenge were
prepared by incubating at 37°C in the appropriate atmo-
sphere for 4 to 5 hours (early stationary phase), 7 hours
(stationary phase), or 15 to 20 hours (late stationary
dia Growth phase Viable count
Late stationary phase 109 CFU/mL
Late stationary phase 109 CFU/mL
%
5%
Early stationary
phase
109 CFU/mL
%
5%
Early stationary
phase
109 CFU/mL
Late stationary phase Bacterial suspension
sterilized through
0.45-m filter
Stationary phase 50% of bacterial
suspension
sterilized through
0.45-m filter and
50% heat
inactivated
oth BBL
vated
d 5%
nt BBL
Late stationary phase 109 CFU/mLre me
ith 70
6 and
ith 70
6 and
soy br
inacti
rum an
richmephase) according to growth curves.
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soy broth BBL (Becton Dickinson, Sparks, MD) supple-
mented with 10% inactivated horse serum (National Vet-
erinary Institute, Uppsala, Sweden) and 5% Fildes enrich-
ment BBL (Becton Dickinson). All other bacterial species
were inoculated into BHI broth BBL with or without 70%
CMRL-1066 (ICN Biomedicals, Costa Mesa, CA) and 5%
fetal bovine serum (Invitrogen, Lidingö, Sweden). Heat-
killed bacteria were boiled for 15 minutes. Viable counts
of all inocula were performed before challenge.
Immunohistochemistry
Consecutive 6-mm sections from the two patients with
early T1D and the control donors were processed and
labeled using a standard immunoperoxidase technique
for paraffin section. With the exception of chromogranin A,
glucagon, and insulin, all other antigens were unmasked by
heat-induced epitope retrieval. Antibodies against chromo-
granin A (NeoMarkers, Thermo Fisher Scientific Inc, Fre-
mont, CA) were used to identify islets. Antibodies against
macrophages (CD68), granulocytes [myeloperoxidase
(MPO)], and glucagon were from Dako (Glostrup, Den-
mark), whereas antibodies against insulin and CD3 were
from BioGene (Kimbolton, UK) and Novocastra (Leica Mi-
crosystems AB, Stockholm, Sweden), respectively. Bound
antibodies were visualized with Dako EnVision (Dako).
Consecutive sections from rats were processed using
the same technique. Antibodies against leukosialin
(CD43, all leukocytes except B cells), macrophages
(ED1/CD68 and ED2/CD163), and T cells (CD3 and CD8)
were from AbD Serotec (Dusseldorf, Germany); antibod-
ies against insulin and glucagon were from Dako. The
mouse antibody against insulin was from Sigma-Aldrich
(St. Louis, MO). Bound antibodies were visualized using
Dako EnVision or EnVision DuoFLEX Doublestain System
(both Dako) and diaminobenzidine-based substrate or
3-amino, 9-ethyl-carbazole (Dako). Sections were coun-
terstained with hematoxylin and analyzed by light micros-
copy.
Isolation and Culture of Human Islets
Islets of Langerhans were isolated as described previ-
ously.39 Islet preparations were of good quality but were
made available for research because of a too low total islet
number for clinical transplantation. Islets were kept in cul-
ture bags (Baxter Medical AB, Kista, Sweden) with 200 mL
of CMRL-1066 supplemented with 10 mmol/L HEPES, 2
mmol/L L-glutamine, 50 g/mL of gentamicin, 20 g/mL of
ciprofloxacin (Bayer Health Care AG, Leverkusen, Ger-
many), 10 mmol/L nicotinamide, and 10% heat-inactivated
human serum (Uppsala blood bank, Uppsala, Sweden) at
37°C in 5% CO2 and humidified air for 1 to 7 days. The
culture medium was changed on day 1 and then every
other day.Human Islet Function and Cytokine Secretion
in Vitro
Insulin secretion in response to glucose stimulation was
assessed in a dynamic perfusion system. Twenty ran-
domly handpicked islets were exposed to an initial base-
line period with 1.7 mmol/L glucose for 36 minutes. It was
followed by 16.7 mmol/L glucose for 42 minutes and a
final period with 1.7 mmol/L glucose for 48 minutes. Frac-
tions were collected at 6-minute intervals. The insulin con-
centration was determined by enzyme-linked immunosor-
bent assay (Mercodia, Uppsala, Sweden), and the
stimulation index [(insulin released per minute during high
glucose concentration)/(insulin released per minute during
low glucose concentration)] was calculated. For measure-
ments of insulin and DNA, 20 islets were randomly hand-
picked. Quant-iT picogreen dsDNA assay kit (Picogreen;
Invitrogen) and a fluoroscan ascent FL (Thermo Electron
Corp, Waltham, MA) were used for DNA measurements.
Approximately 100 to 150 handpicked islets from 7
patients were cultured in 2 mL of CMRL-1066 supple-
mented with 10% fetal calf serum with or without the
addition of LPS (1 g/mL; InvivoGen, Toulouse, France),
LTA (15 or 30 g/mL; InvivoGen) or a combination of the
two bacterial components. Supernatants were collected
after 24 hours, and the concentrations of IL-8, IL-6 (R&D
Systems, Oxford, UK), and monocyte chemotactic pro-
tein 1 (MCP-1) (Serotec, Oxford, UK) were measured on
a Gyrolab workstation (Gyros AB, Uppsala, Sweden).
Statistical Analysis
Differences in cytokine secretion and blood works were
analyzed with Wilcoxon signed rank test. P  0.05 was
considered statistically significant. Data are presented as
mean  SEM.
Results
Morphology of the Human Pancreas at T1DOnset
The pancreases of patients 1 and 2 had a normal mac-
roscopic appearance. Morphologic examination of bi-
opsy specimens retrieved from several sites before islet
isolation revealed extensive ductal fibrosis and normal
number and distribution of islets in both patients. How-
ever, the appearance of the -cells within the islets dif-
fered markedly between the two patients.
Patient 1 died only a few days after the first symptoms of
impaired glucose metabolism and exhibited an increased
inflammation within the entire pancreas (Figure 1). The in-
flammatory reaction and the number of insulin-positive
cells within the islets varied markedly among different
lobes. Three categories of islets were observed: i) islets
containing a markedly reduced number of -cells (Figure
1, A and B, and Figure 2A), ii) islets without -cells (Fig-
ure 1, C and D), and iii) islets with an apparent normal
number of -cells (Figure 2C). Each lobe of the pancreas
contained one predominant category of islets. Slightly
increased numbers of CD3 (T cells), CD68 (mono-
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AJP November 2012, Vol. 181, No. 5Figure 1. Immunopathologic analysis of the pancreas of patient 1. A pancreatic lobe containing islets with only a few -cells stained for insulin (brown, A) and
chromogranin (brown, B). Another lobe of the pancreas with islets with no -cells stained for insulin (brown, C) and chromogranin (brown, D). Almost all ducts
had periductal fibrosis (A–F). Accumulation of CD3 (brown, E) and MPO polymorphonuclear cells (brown, F) close to a duct. Migration of MPO cells from
ducts into surrounding exocrine parenchyma (F and G). Marked infiltration of MPO polymorphonuclear cells in one pancreatic lobe but not in the adjacent lobe
(F–H). Necrotic areas surrounding pancreatic ducts with intense inflammation of MPO polymorphonuclear cells in a pancreatic lobe. The adjacent lobe has a
normal appearance. Original magnification: 25 (D–F) and 100 (E–H).
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AJP November 2012, Vol. 181, No. 5Figure 2. Immunopathologic analysis of the pancreas of patients 1 (A, C, and H) and 2 (B, D, E, F, and G). Islets with only a few remaining -cells (brown, A
and B). Islets with an apparently normal number of -cells (brown, C–G). All types of islets have various degrees of hydropic degeneration and failing -cells
(brown, A–G). Intraislet bleeding (D). Periductal fibrosis (pink, Van Gieson staining). Original magnification: 400 (A, C–F), 200 (B and G), and 100 (H).
A New Animal Model in Diabetes Research 1741
AJP November 2012, Vol. 181, No. 5cytes and macrophages), and MPO (neutrophil granu-
locytes) cells were found, and they were often localized
around pancreatic ducts, in septa between pancreatic
lobes, but also within the pancreatic parenchyma in cer-
tain lobes (Figure 1, E–H). Occasionally, necrotic areas
with intense inflammation of MPO cells were found (Fig-
ure 1H). Clusters of immune cells were frequently ob-
served, a few times within or close to the islets but more
often in the exocrine pancreas without any apparent as-
sociation to the islets. Staining for CD8 (cytotoxic T cells)
and CD4 (helper T cells) revealed that most of the pres-
ent CD3 cells were CD8.
In the pancreas of patient 2, who died after 3 to 4
weeks of symptoms of impaired glucose metabolism,
depositions of fat were frequently observed within the
exocrine parenchyma. T cells, both CD4 and CD8,
CD68 macrophages, and MPO cells were found in
numbers similar or less than those observed in pancre-
ases obtained from donors without any history of diabe-
tes or pancreatic disease. The immune cells were scat-
tered within the pancreatic parenchyma without any
apparent accumulation in or around the islets. Most of the
-cells in almost all examined islets had signs of severe
hydropic degeneration, which is characterized by a swol-
len cytoplasm but preserved nucleus (Figure 2, B and
D–G). In some islets, intraislet hemorrhages or pro-
nounced dilatations of the intraislet capillaries were found
(Figure 2D). Most of the glucagon-positive cells had nor-
mal morphologic features, but some -cells in the most
affected islets had a swollen cytoplasm.
Macroscopic Findings in the Rat Pancreas
All animals tolerated the surgical procedure well. No mac-
roscopic changes were observed in any other internal or-
gan but the pancreas. Likewise, no changes in aspartate
aminotransferase, alanine aminotransferase, alkaline phos-
phatase, antitrypsin, orosomucoid (1-acid glycoprotein),
haptoglobin, and C-reactive protein were detected in rats
with bacteria installed in the pancreatic duct when com-
pared with animals exposed to BHI without bacteria.
Four different bacterial species were used for the chal-
lenge (Table 1). Early stationary-phase bacteria induced
a general infiltration of immune cells in the pancreatic
parenchyma. After 2 days, these rats had developed a
picture congruent with acute pancreatitis; therefore, only
late stationary-phase bacteria, heat-killed bacteria, bac-
terial components, or mixtures thereof were used in the
following experiments.
Animals challenged with the gram-negative E. coli ex-
hibited regional areas of edema in their pancreases. The
three gram-positive bacteria included in the study in-
duced no or minimal macroscopic changes.
Microscopic Findings in the Rat Pancreas
After the macroscopic inspection, the pancreas was di-
vided into three parts for microscopic examination: the
head, the corpus, and the tail. Control animals exposed to
BHI broth had normal morphologic findings without in-
creased infiltration of immune cells and with intact islets.In animals challenged with bacteria, there were re-
gions of the pancreases that exhibited infiltration of
mainly polymorphonuclear cells, with no difference
among the three strains of rats used. This cellular infiltra-
tion was present as early as 1 to 2 hours after bacterial
instillation (Figure 3, A and B). It increased in intensity in
animals examined after 3 to 5 hours and was commonly
localized to areas around the pancreatic ducts (Figure 3,
C–H). Islets of Langerhans situated in the vicinity of the
ducts often seemed to attract polymorphonuclear cells
(Figure 4, B and C), which clustered at the border be-
tween the islet and the exocrine parenchyma or infiltrated
the islets (Figure 4, D–F). Minor hemorrhages or dilated
capillaries were frequently noted within the islets (Figure
3H). A large fraction of the islet cells revealed signs of
severe cellular damage in the form of hydropic degener-
ation (Figure 3H and Figure 4, C, E, G, and H). Several
islets surrounded by polymorphonuclear cells contained
cells with totally destroyed cellular architecture. The exo-
crine cells were almost intact, but in the areas with the
most intense inflammation the exocrine cells also re-
vealed signs of degeneration.
Immunohistochemistry
Control animals instilled with BHI broth had a normal
morphologic appearance and distribution of both insulin-
positive and glucagon-positive cells in their pancreases.
Only occasional CD68 cells were scattered within the
pancreatic parenchyma. Both the frequency and distri-
bution of these cells were the same as observed in un-
challenged control animals.
The polymorphonuclear cells described herein in ani-
mals exposed to bacterial instillation in the ductal system
were CD43. Most of these cells were also MPO (neu-
trophil granulocytes), and the remaining cells were
CD68 (monocytes and macrophages). Staining for
CD3, CD8, and CD168 (activated macrophages) resulted
in only a few positive cells at frequencies comparable
with those recorded in control rats. Insulin and glucagon
staining demonstrated that most of the islet cells with
hydropic degeneration were -cells, but some -cells
had signs of cellular damage.
Animals challenged with E. coli had the most intense
pancreatic inflammation, often with accumulation of
CD43 MPO cells in clusters (Figures 3 and 4). In af-
fected lobes, -cells in both infiltrated islets and noninfil-
trated islets were hydropically degenerated. If the E. coli
was heat killed, the intensity was clearly reduced, and the
generated immune reaction resembled instead that de-
scribed for the gram-positive cocci. The intensity of the
inflammation and the infiltration pattern did not change if
a combination of E. coli and Enterococcus faecalis was
used (Table 2).
Animals inoculated with enterococci or -hemolytic
streptococci induced an infiltration of CD43 MPO cells
of moderate intensity (Figures 3 and 4). The CD43
MPO cells accumulated around ducts, in septa be-
tween the pancreatic lobes, and within some of the pan-
creatic lobes. The clustering tendency was, however, not
as apparent as in animals inoculated with E. coli.
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AJP November 2012, Vol. 181, No. 5Figure 3. Progressive inflammation and islet destruction after installation of bacteria [E. faecalis in the late stationary phase (A–D) or E. coli in the late stationary
phase (E–H)] in the ductal compartment of healthy rats at 1 hour (A and B), 3 hours (C and D), 5 hours (E and F), and 4.5 hours (G and H). Progressive migration
of MPO polymorphonuclear cells (brown, A, C, E, and G) from the ducts into the surrounding pancreatic tissue, often with accumulation around islets.
Consecutive sections reveal progressive destruction of the -cells and development of hydropic degeneration (insulin positive cells in brown, B, D, F, and H).
After 4.5 hours, islets show dilatation of capillaries and intraislet bleedings (H). Original magnification: 200 (A–D and G–H) and 100 (E and F).
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AJP November 2012, Vol. 181, No. 5Figure 4. Islet inflammation destruction after installation (4 to 5 hours) of bacteria [E. faecalis in the late stationary phase (A and D) or heat-inactivated stage (B),
E. coli in the late stationary phase (C, E, and G), -streptococcus in the late stationary phase (F), or S. aureus suspension sterilized through 0.45-m filter (H)]
in the ductal compartment of healthy rats. A: Migration of CD43 leukocytes from a small duct (red arrow) and accumulation around neighboring islets (yellow
arrows). B:Migration and accumulation of MPO cells from a duct (lower part of the figure) to one, but not the other, of two neighboring islets (yellow arrows).
C: Migration and accumulation of CD43 cells from a duct to a neighboring islet. D: Accumulation of polymorphonuclear cells around an islet. E and F:
Accumulation and infiltration of leukocytes (CD43 , brown) in an islet, with several -cells (insulin, red) revealing hydropic degeneration. G and H: Islets with
advanced hydropic degeneration and failing -cells (insulin, brown, A–G). Original magnification: 25 (A), 200 (B–E), and 400 (F–H).
filtrating
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in Vitro
Islets of Langerhans could be obtained from both pa-
tients with T1D applying a routine islet isolation proce-
dure for the pancreases obtained from diseased organ
donors. However, the total number of islets obtained from
the patients with T1D was reduced, implying that only the
most intact islets could be secured for in vitro studies.
Islet insulin content was severely reduced in islets from
both patients with T1D (Table 3). Glucose-stimulated in-
sulin release in control islets had a clear biphasic re-
sponse, which could not be demonstrated in islets from
patients 1 or 2 (Table 3). Expression of inflammatory
mediators in islets from T1D patients was in the same
range as that found in control islets (Table 3).
Islets obtained from control donors that were exposed
in vitro to LPS and LTA induced a significant increase in
the secretion of IL-6 and IL-8, whereas MCP-1 needed
the presence of LPS to reach significantly increased lev-
els (Table 4).
Table 2. Morphologic Evaluation of Rat Pancreases Inoculated w
Bacterial species
Occasional cellular infiltration (CD
Periductal Interlobular septa Exocrine tiss
E. coli (n  12)  to   to   to  o
accumulatin
clusters in
affected lob
E. faecalis
(n  12)
 to   to   to  diffu
spread with
affected lob
E. coli and E.
faecalis (n  6)
 to   to   to  o
accumulatin
clusters in
affected lob
S. aureus
(preparation A)
(n  12)
0 0 0
S. aureus
(preparation B)
(n  4)
0 to  0 to  0 to 
-Streptococcus
(n  6)
 to   to   to  diffu
spread with
affected lob
Controls (n 9). Cellular infiltration was graded in 4 categories: 0, occa
cells; , moderate number of infiltrating cells; and , high number
*More pronounced than expected when considering the amount of in
HD, hydropic degeneration.
Table 3. Characteristics of Isolated Islets
Islet parameter Co
Stimulation index
Insulin content, ng/ng of DNA 3
ADP/ATP ratio 0.
Tissue factor content, pmol/g of DNA 0.
MCP-1, pmol/g of DNA 0.
IL-6, pmol/g of DNA 0.0
IL-8, pmol/g of DNA 0.*The total amount of insulin secreted was at nonstimulated levels.
ADP, adenosine diphosphate; ATP, adenosine triphosphate.Discussion
A new animal model was generated with an aim to repro-
duce the initial events of T1D. Findings obtained after
inoculation of human pathogens in the pancreatic ductal
compartment of healthy rats revealed marked similarities
with those observed in the pancreases of patients dying
at onset of T1D. Obtained results suggest that a bacterial
trigger for T1D is plausible (ie, a local inflammatory reac-
tion caused by bacteria, probably entering from the in-
testine to the ductal system of the pancreas, activates an
innate injurious immune response, predominantly caus-
ing periductal and islet inflammation and comprising
-cell destruction) (Figure 5).
Bacteria entering through the papilla Vateri are known
to occur in humans (eg, bacterial infections of the bile
ducts). Enteric bacteria, especially enterococci and
E. coli, are usually involved in acute pancreatitis.40,41
These bacterial species, together with -hemolytic strep-
tococci that often colonize the human duodenum, were
therefore chosen for the animal experiments. Because
rious Bacteria in the Ductal System
PO cells) Intact islet features
Islets
Insulin-
positive
cells
Glucagon-
positive
cells Vasculature
 to  peri- and
intraislet infiltration
Severe
HD
Occasional
HD
Dilatated capillaries,
occasional
bleedings
to  predominantly
peri-islet infiltration
HD Intact Dilatated capillaries
 to  peri- and
intraislet infiltration
Severe
HD
Occasional
HD
Dilatated capillaries,
occasional
bleedings
0 HD* Intact Intact
to  HD* Intact Dilatated capillaries
to  predominantly
peri-islet infiltration
HD Intact Dilatated capillaries
ells, in numbers similar to untreated controls;, low number of infiltrating
rating cells.
cells.
lets Patient 1 Patient 2
0.8* 1.9*
.5 0.092 0.26
.01 0.05 0.05
.009 0.031 0.067
.002 0.02 0.019
.0007 0.01 0.0006
.006 0.04 0.1ith Va
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AJP November 2012, Vol. 181, No. 5acute onset of T1D has been reported in a child with toxic
shock syndrome due to S. aureus,42 a toxin-producing
staphylococcal strain was also included. However, be-
cause of its high virulence this strain was never used
alive.
Early stationary-phase bacteria induced acute infec-
tions and necrosis. With stationary-phase or heat-killed
bacteria the picture altered. A tentative initial scenario for
T1D could therefore be that after contact with the pan-
creatic juice29 dying or dead bacteria entrapped in the
ductal system within a segment of the pancreas release
toxins and cell-wall components (Figure 5) (eg, LPS and
LTA). These substances trigger an innate injurious re-
sponse mainly centered around affected ducts. However,
bacterial components could subsequently reach neigh-
boring islets via arterioles arising from blood vessels
draining the ducts.43 Dying -cells that release tissue-
specific antigens within a proinflammatory microenviron-
ment provide optimal conditions for antigen-presenting
cells that could trigger an acquired immune response (ie,
islet specific autoimmunity, including autoantibodies44
and in some patients also autoreactive T cells45). Such a
T-cell–mediated response is, however, not expected to
arise until after several days and is therefore beyond the
scope of the present study.
Table 4. Secretion of IL-8, IL-6, and MCP-1 from Human Islets
Exposed to LPS, LTA, or Both
Control LPS LTA LPS and LTA
IL-8 322  104 933  188* 1190  500* 1136  322*
IL-6 53  24 121  49* 162  71* 119  36*
MCP-1 131  42 254  71* 282  156 273  99*
Mean  SD concentrations of IL-8, IL-6, and MCP-1 are presented in
picomoles per milliliter.
*P  0.05 versus control medium.
 Insufficiency in papilla Vateri is likely to occur more
frequently during periods with rapid growth because of
both the enlargement of the intestine and the pancreas.
Interestingly, the HLA genotypes (HLA-DQ2/8, DQ8/
0604, and DQ8/X) conferring an increased risk for T1D
are also linked to increased birth weight,46 and several
studies found that children affected by T1D have in-
creased body weight, are taller, and have higher BMI
than controls.47–51
Cytokine-mediated toxicity has been implicated in the
development of T1D. However, even if human -cells are
vulnerable to proinflammatory cytokines,52 no plausible
hypothesis has been presented to explain why these
inflammatory cytokines would accumulate in the islet vi-
cinity. Dying bacteria within the ductal system of the
pancreas could provide such a mechanism. Released
LPS and LTA trigger ductal epithelium and islets to re-
lease IL-6, IL-8, and MCP-1, with chemoattractive capac-
ity to recruit mainly neutrophilic granulocytes and mono-
cytes. These cell types were found rapidly accumulating
in large numbers adjacent to the islets in affected lobules
of the pancreas within only a few hours after the bacterial
instillation. These infiltrating cells could induce functional
impairment and death of -cells because of their inherent
low protection against proinflammatory cytokines, nitric
oxide, and reactive oxygen species,53 especially under
hyperglycemic conditions.54 An injurious innate immune
response triggered by bacteria would affect only a lobe
or a segment of the pancreas, whereas islets in adjacent
pancreatic lobes would remain unaffected. This scenario
is in agreement with findings in humans with T1D.55 The
peculiar organization of the endocrine pancreas in small
clusters of cells (islets of Langerhans, apparently ran-
domly distributed within the pancreas56) could possibly
serve as a mechanism of protection from the develop-
Figure 5. Bacteria unintentionally entering the
ductal system of the pancreas rapidly succumb
to the antibacterial effects of the pancreatic juice
and release bacterial components, such as LPS,
LTA, and various toxins. In response, ductal ep-
ithelial cells and islets of Langerhans receiving
blood from the affected ductal area attract poly-
morphonuclear cells via release of IL-6, IL-8, and
MCP-1. Infiltrating cells induce functional im-
pairment and death of -cells because of their
inherent low protection against proinflammatory
cytokines, nitric oxide (NO), and reactive oxy-
gen species (ROS). Glucotoxicity and lipotoxic-
ity, as well as autoimmunity, are superimposed
and contribute to the progression into clinically
overt T1D. The periductal area of the pancreas is
similarly affected by the innate inflammation,
leading to loss of exocrine parenchyma and peri-
ductal fibrosis. 
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pancreatic ductal system.
The immunopathologic findings observed in the rat
model reveal marked similarities to the findings in the
patient dying within only a few days of T1D (ie, an ongo-
ing injurious inflammatory process in certain lobes of the
pancreas with occasional necrotic areas densely infil-
trated by neutrophilic granulocytes). Other areas of the
pancreas in patient 1 had signs of preceding assaults,
with increased periductal fibrosis and lobes containing
islets without ongoing inflammation but with no or only a
few -cells. A few authors have reported self-resolving
T1D57 or fluctuating symptoms of T1D several months
before the diagnosis of T1D.58 These and other clinical
observations led to the formulation of a model for the
development of T1D59 in which a progressive loss of
-cell mass over several years is postulated. These find-
ings are in agreement with an injurious innate immunity
reaction repeatedly occurring at certain episodes, but not
with an acquired T-cell–mediated immune assault, which
is expected to occur rapidly and should not vanish until
all -cells are eliminated.
In both patients who died at onset of T1D, large areas
of the pancreas contained islets with an apparently nor-
mal number of -cells, and it is difficult to envision that the
remaining -cell mass would be unable to control the
glucose metabolism, implying a severe functional impair-
ment possibly caused by an intense innate inflammation
as that present in patient 1. It is tempting to speculate that
the -cells present in the pancreas of patient 2 initially
were also affected by an ongoing inflammation and there-
fore unable to respond adequately to high glucose. When
the innate immune response vanishes, some -cells
would escape this functional impairment. However, the
metabolic challenge faced is insurmountable (35
mmol/L glucose),60 making the -cells succumb to glu-
cose (lipid) toxicity. This adverse process would gradu-
ally affect more and more -cells because at each point
of time the number of functionally responsive -cells is
too low to normalize blood glucose concentrations. Hy-
dropic degeneration of the -cells was previously de-
scribed approximately 100 years ago in patients dying at
onset of T1D,61 and similar findings have been reported
in a number of different conditions of prolonged periods
of hyperglycemia.62 This intracellular edema seems,
therefore, to develop in response to -cell exhaustion.
In conclusion, we present a novel animal model for the
initial events triggering T1D that reveals marked similarities
with the morphologic findings in patients dying at onset of
T1D. Currently, only a few animal models of T1D are avail-
able.1 The nonobese diabetic mouse and BioBreeding-di-
abetes prone rat predominate in the scientific literature.
Although these models have generated valuable data, they
are both hampered by their need for special husbandry
procedures. Studies on possibly important environmental
triggers of T1D are thereby excluded. The presented new
model of T1D is not strain specific, and no special hus-
bandry conditions are necessary. With longer observa-
tion periods, it may also answer questions such as why
some epitopes recognized by autoreactive T cells from
patients with T1D are homologous to Streptococcus pyo-genes exotoxin A and S. aureus enterotoxin B63 and how
a deranged enteric flora takes part in the development of
T1D and celiac disease.64,65 Both diseases are increas-
ing in incidence and to some extent share HLA risk ge-
notypes (HLA-DQ2/8) and genes involved in intestinal
permeability.65 Notably, patients with celiac disease also
have an enteric shift toward staphylococci and gram-
negative enterobacteria.
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